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Learning objectives
• Needs and problems of switch
• Evidence about efficacy of switch
• Paliperidone 
• Clinical practice of switching 
antipsychotics
Pharmacokinetics vs. Pharmacodynamics
Drug
dose
Plasma
concentration
Tissue
concentration
Pharmacological
effects
Metabolites
Excretion of 
drugs and
metabolites
Behavioral 
effects
Variability is the major determinant of the dose-effect 
relationship in patients
D2-Receptor Occupancy Fluctuation with 
Simulated Repeated Dosing
Karlsson P et al., Poster
IR 3 mg/d: Fluctuation = 64 – 83%
ER 6 mg/d: Fluctuation = 75 – 78%
What is the prescribing pattern
Bret P, Bret MC, Queuille E.  Prescribing patterns of antipsychotics in 13 French psychiatric hospitals.Encephale. 2009 Apr;35(2):129-38.
SGAs have become the first-line treatment for psychiatric disorders.
Case
Q2 To which APD 
Switch to Paliperidone
Switch to Paliperidone
COMBINATION ATYPICALS: 1.Suzuki.T, Human psychopharmacology 2008; 23:455-463
2.Chan J, Journal of Psychopharmacology21(6) (2007) 657-664
• Side effect   
• Lack of efficacy
• Appropriate 
setting
• Social support
• Risk factors 
• Inpatient set up
• Outpatients    
Switch:
when do we change APD?
How to select new APD
Acute Episode
Relapse
Selecting 
Antipsychotics 
Why do patients discontinue medication? 
CATIE 1
Weiden PJ.J.Clin Psychiatry 2007;68 [suppl 1]:12-19
CATIE – Phase 3, Symptom response
Drugs ARIP CLOZ COMB FLU-D OLAN PERP QUET RISP ZIPR P-
value
PANSS –
3 
months
0.506 0.002
✓
0.002 0.005
✓
0.002
✓
0.084 0.013 0.044 0.045 0.832
✖
PANSS-6
✔✔
0.006 <0.001
✔
0.43 0.003
✔
0.018 0.100 0.009 0.371 0.515
✖
• Outcome of switch is  dependent upon
– Medication switched to
– Medication switched from.
•
Model of factors that influence decision
Weiden PJ, J.Clin.Psychiatry, 2007;68(suppl 1)

Criteria's for Response 
• Considerable divergence of 
expert opinion
• One survey of experts 
indicated that a period of 
2.6 to 5.5 weeks was 
required.
• Lack of minimal response 
after 1 or 2 weeks is a 
powerful Predictor of 
subsequent poor response   
6 weeks         12 weeks                  ???
APA Working group 2005
Symptom, Severity & Duration: A dimensional approach 
Efficacy and safety of oral paliperidone extended-release tablets in the treatment of 
acute schizophrenia: pooled data from three 52-week open-label studies.
Emsley R, Berwaerts J, Eerdekens M, Kramer M, Lane R, Lim P, Hough D, Palumbo J.
Int Clin Psychopharmacol. 2008
• This analysis shows that 
paliperidone extended-
release can maintain 
improvements in symptoms 
and functioning and is 
generally well tolerated for 
up to 52 weeks in 
schizophrenia patients.
Kramer et al. J Clin Psychopharmacol, 2007
p<0.001 paliperidone vs. placebo
Paliperidone: Delayed Symptom 
Recurrence
Does the remission sustain??
Randomized, Double-
Blind, Placebo-
Controlled Study of 
Paliperidone Extended-
Release and Quetiapine 
in Inpatients With 
Recently Exacerbated 
Schizophrenia
Canuso CM, Dirks B,  Randomized, Double-
Blind, Placebo-Controlled Study of 
Paliperidone Extended-Release 
and Quetiapine in Inpatients With Recently 
Exacerbated Schizophrenia. Am J 
Psychiatry. 2009 May 1 
Is paliperidone better than 
other AAPD?
For which symptom domain it 
works best?
Direct and indirect effects of paliperidone extended-release tablets on 
negative symptoms of schizophrenia.
Turkoz I, Bossie CA, Dirks B, Canuso CM.
Ortho-McNeil Janssen Scientific,: Neuropsychiatr Dis Treat. 2008 Oct;4(5):949-58
• Path analysis indicated that 
up to 33% of negative 
symptom improvement was 
a direct treatment effect.
• Negative symptom 
improvement also was 
indirectly mediated via 
changes in positive and 
depressive symptoms.
Expected clinical benefits of 
paliperidone extended-release formulation
when compared with risperidone immediate-release.
Pani L, Marchese G.Expert Opin Drug Deliv. 2009
Is it same or better than Risperidone
KW, 20 years, FES admitted 3 weeks, discharged in ‘good 
remission’ Olan 10 mg BID, April 2008

Partial or 
No Response
Texas Algorithm, 2006 
What are evidence-based recommendations for selecting Antipsychotic medication?
Consider earlier trail of clozapine in atients with a H/O recurrent suicidality, 
violence, or comorbid substance abuse. Persistence of positive symptoms 
> 2years warrants & >5 years requires a clozapine trial, independent of number of  
antipsychotic trials.
Benefits of switching 

Antihistaminic Effects 
of Antipsychotics
Adapted from Weiden, P. J., 2007
* Sedation is dose-related and usually abates after several weeks.
†
Sedation also possible; insomnia usually abates after several weeks.
Clozapine
Quetiapine*
Olanzapine*
Risperidone
Haloperidol
Ziprasidone †
Aripiprazole †
Insomnia
Sedation
}
}
Incidence of Cardiac Adverse Events Occurring in ≥ 5% of 
Patients, n (%)
AE Placebo
N=355
3 mg
N=127
6mg
N=235
9mg
N=246
12mg
N=242
15mg
N=113
Tachycardia 10 (3) 3 (2) 17 (7) 18 (7) 18 (7) 2 (2)
Sinus 
Tachycardia
15 (4) 11 (9) 9 (4) 10 (4) 17 (7) 8 (7)
QTc 
Prolongation
9 (3) 4 (3) 9 (4) 7 (3) 12 (5) 4 (4)
Paliperidone ER Groups
Meltzer et al. ICOSR 2007
No clinically relevant difference between proportions of QTc in pali vs. placebo groups (1.6% vs. 1.4%)
EPS-Related Adverse Events
Placebo 3mg 6mg 9mg 12mg 15mg
Percent 11 13 10 25 26 24
Paliperidone ER Groups
Depot Injections
• Paliperidone ER 12 mg/day 
was superior to placebo 
from baseline in YMRS score 
, from day 2 to endpoint. 
• Paliperidone 3,6 & 12 mg 
were safe well tolerated in 
patients with bipolar I 
disorder experiencing acute  
manic or mixed episode.
• Initiated as 150 mg eq. IM 
deltoid injection, 
• Achieved plasma 
concentration associated 
with effective symptom 
control.
• Subsequent monthly dosing 
maintained clinically and 
statistically effective 
response across 25-150 
mg.eq
Bipolar Disorder 
Switching to a new medication yielded no advantage over 
staying on the previous 
medication. Staying on olanzapine was associated with 
greater weight gain. 
Outcome switching: CATIE, 2009 
Clinical benefit in switching antipsychotics
• Previous CATIE 
demonstrated equal 
efficacy in Head-head trial
• This study reiterates equal 
benefit in switching
• Limitations
• Subjects were not ‘unresponsive' dose, 
duration of previous APD was not known, so 
‘mirror-image’ comparison was not possible
Weight Gain Comparision
of Atypical Antipsychotics
Incidence of ≥7% Increase in Body Weight in Short-Term Trials*
5.1
7.9
9.8
18.0
23.0
29.0
3.7
5.0
4.0
9.0
6.0
3.0
0
5
10
15
20
25
30
Aripiprazole** Paliperidone
ER***
Ziprasidone Risperidone Quetiapine Olanzapine
Pe
rc
en
t o
f P
at
ie
nt
s 
(%
)
Placebo
*Based on United States Product Inserts
**Error bars reflect reporting of weight gain in PI by baseline BMI
***confirmation of US PI
1 in 3
1 in 4
1 in 51 in 101 in 121 in 19
Metabolic profiles of second-generation antipsychotics in early psychosis: 
Findings from the CATIE study.2009
Patel JK, Buckley PF  Metabolic profiles of second-generation antipsychotics in early psychosis: Findings from the CAFE study.
Schizophr Res. 2009 Jun;111(1-3):9-16. Epub 2009  
(J Clin Psychiatry 2007;68[suppl 4]:34–39) 
WHO IS A CANDIDATE FOR SWITCHING?
Expert Consensus Guidelines recommend 
the combination of psychosocial interventions 
plus a trial switch to an antipsychotic with less weight gain liability. 
Monitoring Guidelines
Side effects of Antipsychotics
Seizure, Arrhythmias, Blood count, Prolactin, Weight , & Metabolic
• Atypical antipsychotic drugs and the risk of sudden cardiac Death ,
– LH . N Engl J Med. 2009 May 14;360(20):2137;[Potentially lethal cardiac side effects caused by psychiatric drugs] Sawicke L, Sturla S.Vertex. 
2008 Nov-Dec;19(82):387-93
• [Hematological adverse effects caused by psychiatric drugs  
– Mazaira S.Vertex. 2008 Nov-Dec;19(82):378-86
• Akathisia and second-generation antipsychotic drugs
– Kumar R, Sachdev PS. Curr Opin Psychiatry. 2009 May;22(3):293-99.
• Antipsychotic agents and cardiometabolic morbidity in youth. 
– Kruszewski SP, Paczynski RP.Arch Pediatr Adolesc Med. 2009 Apr;163(4):394-5; author reply 395
• Weight gain, metabolic parameters, and the impact of race in aggressive 
inpatients randomized to double-blind clozapine, olanzapine or haloperidol.
– Krakowski M, Czobor P, Citrome L.Schizophr Res. 2009 May;110(1-3):95-102
• Association between antipsychotic drugs, antidepressant drugs, and venous 
thromboembolism.
– Lacut K.Clin Adv Hematol Oncol. 2008 Dec;6(12):887-90.
• Antipsychotic-induced hyperprolactinemia.
– Bostwick JR, Guthrie SK, Ellingrod VL.Pharmacotherapy. 2009 Jan;29(1):64-73.
SWITCHING STRATEGIES FOR 
ANTIPSYCHOTIC MEDICATION 
Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for 
improving therapeutic outcomes. J Clin Psychiatry 2007;68(suppl 6):10–13  
Switching only changes nature of Problem
• Do’s ( check list ) 
– Measuring clinical condition
– Physical health
– Base line investigation ( EKG, 
Blood work )
– Explain 
– Review all medications 
– Attention to D-D-I ( take help 
from Pharmacist)
– Read new information 
– Monitor 
– Frequent appointment
• Quantification and 
measurement in psychosis
– SAPS-SANS
– PANSS
– BPRS
– HDRS
– ADL
– GAF
– QOL
Clinical Consequences of switching
• Good experience for every one
– Do not reduce the level of monitoring
– Late consequences and     Risk of non-compliance.
• Into bigger problem
– Withdrawal symptoms of 
antipsychotic
– Increase in secondary 
symptoms ( anxiety-insomnia)
– Persisting side effects of prior 
APD
– Emergence of new psychiatric 
symptoms
– Side effects of newer APD
– Break-through Psychosis
– Fall, giddiness, fainting, 
– Emergency situation ( Seizure, 
low blood count, Cardiac event, 
Steven-Johnston)
Differences in effects on fasting triglyceride levels were also 
found between agents in a short, open-label, parallel- group   
SWITCHING STRATEGIES 
Pfizer Inc. Briefing Document for Zeldox Capsules (zipra- sidone HCl). Submitted to FDA 
Psychopharmacological Drugs Advisory Committee; July 19, 2000. Available at: 
http://www.fda.gov/ohrms/dockets/ac/00/backgrd/ 3619b1a.pdf. Accessed Dec 15, 2006 
Determinants of outcome in schizophrenia
Relapse
Drug 
Discontinuation
Non-adherence is a sign of Partial or Complete 
Non-response
Non-adherence or discontinuation is associated 
(marker) of poor efficacy
Final message 
• Switching should be NOT be a priority situation.
• It does not give any superiority in terms of efficacy amongst SGA except 
clozapine
• Outcome of switch depends upon both the previous and the new 
molecule
• The first clinical option should be optimization of dose, schedule, 
education & non-drug therapies.
• It should be opted only if clinical conditions are compelling
• Whenever switch, due consideration should be given to all denominators 
of its outcome.
• Not to compromise efficacy 
• Not to continue with side effects
